<p>美國銀行證券分析師傑森·澤曼斯基今天重申了對 Madrigal Pharmaceuticals 的持有評級，並設定了 550.00 美元的目標價。</p>
<h3>在 TipRanks 上享受 55% 的折扣</h3>
<ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
<p>根據 TipRanks，澤曼斯基是一位五星級分析師，平均回報率為 21.3%，成功率為 57.59%。澤曼斯基覆蓋醫療保健行業，專注於 Ligand Pharma、Insmed 和 Cytokinetics 等股票。</p>
<p>目前，分析師對 Madrigal Pharmaceuticals 的共識評級為強烈買入，平均目標價為 663.89 美元。</p>

Madrigal制藥

醫藥突破 ETF - ALPS

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

紐交所高增長板生物技術指數 ETF - First Trust

標普全球醫療股指數 ETF - iShares

<p>美國銀行證券分析師 Jason Zemansky 對 Madrigal Pharmaceuticals (MDGL) 維持了持有評級，目標價為 550 美元。這位分析師以 21.3% 的平均回報率和 57.59% 的成功率而聞名，覆蓋醫療保健行業。市場對 Madrigal Pharmaceuticals 的共識為強烈買入，平均目標價為 663.89 美元</p>

<p>Bank of America Securities analyst Jason Zemansky reiterated a Hold rating on Madrigal Pharmaceuticals today and set a price target of $550.00.</p>
<div class="lb-trans"><p>美國銀行證券分析師傑森·澤曼斯基今天重申了對 Madrigal Pharmaceuticals 的持有評級，並設定了 550.00 美元的目標價。</p>
</div><h3>Claim 55% Off TipRanks</h3>
<div class="lb-trans"><h3>在 TipRanks 上享受 55% 的折扣</h3>
</div><ul>
<li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions</li>
<li>Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks</li>
</ul>
<div class="lb-trans"><ul>
<li>解鎖對沖基金級別的數據和強大的投資工具，以做出更聰明、更精準的決策</li>
<li>發現表現優異的股票投資理念，並升級到市場領先者的投資組合，使用智能投資者精選</li>
</ul>
</div><p>According to TipRanks, Zemansky is a 5-star analyst with an average return of 21.3% and a 57.59% success rate. Zemansky covers the Healthcare sector, focusing on stocks such as Ligand Pharma, Insmed, and Cytokinetics.</p>
<div class="lb-trans"><p>根據 TipRanks，澤曼斯基是一位五星級分析師，平均回報率為 21.3%，成功率為 57.59%。澤曼斯基覆蓋醫療保健行業，專注於 Ligand Pharma、Insmed 和 Cytokinetics 等股票。</p>
</div><p>Currently, the analyst consensus on Madrigal Pharmaceuticals is a Strong Buy with an average price target of $663.89.</p>
<div class="lb-trans"><p>目前，分析師對 Madrigal Pharmaceuticals 的共識評級為強烈買入，平均目標價為 663.89 美元。</p>
</div>

Bank of America Securities Sticks to Their Hold Rating for Madrigal Pharmaceuticals (MDGL)

Tip Ranks

美國銀行

Ligand制藥

Insmed

細胞動力

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

美國銀行證券維持對 Madrigal 製藥（MDGL）的持有評級